Summit Therapeutics (SMMT) is showing potential for significant growth according to Wall Street analysts, despite facing some financial challenges ahead. Let me provide a comprehensive analysis of their earnings outlook.
## Stock Performance and Price Targets
Summit Therapeutics has shown positive momentum recently, gaining 10.2% over the past four weeks and closing at $25.85 in the last trading session[1]. Wall Street analysts have set a mean price target of $37.38, indicating a substantial 44.6% upside potential from current levels[1]. The price targets range from $30 (16.1% upside) to $44 (70.2% upside), with a standard deviation of $5.71[1]. The relatively tight range suggests moderate agreement among analysts regarding the company’s valuation prospects.
## Earnings Forecasts
The earnings outlook for Summit Therapeutics presents a mixed picture:
**Quarterly Projections:**
– Current Quarter (Q4 2024): Expected EPS of -$0.08[2]
– Next Quarter (Q1 2025): Expected EPS of -$0.08[2]
**Annual Projections:**
– Current Year (2024): Expected EPS of -$0.30[2]
– Next Year (2025): Expected EPS of -$0.36, indicating a projected 20% decline year-over-year[2][5]
The consensus estimates are based on input from 2-3 analysts, depending on the time period[2]. Notably, the company’s earnings are forecasted to show significant declines compared to previous periods, with year-over-year growth estimates at -100% for Q4 2024 and -130.77% for the full year 2024[2].
## Recent Earnings Performance
Summit Therapeutics has shown mixed results in meeting earnings expectations:
– In Q3 2024, the company reported EPS of -$0.08, missing the estimate of -$0.07 by $0.01, resulting in a -14.29% surprise[2]
– In Q2 2024, SMMT reported EPS of -$0.05, beating estimates of -$0.06 by $0.01, a 16.67% positive surprise[2]
– In Q1 2024, the company reported EPS of -$0.05, also beating estimates of -$0.06 by $0.01, a 16.67% positive surprise[2]
The average earnings surprise over recent quarters stands at 6.35%[2].
## Upcoming Earnings Call
Summit Therapeutics hosted its Q1 2025 Financial Results and Operational Progress call on May 1, 2025[4]. The call took place after market close, at 4:30 PM ET[4]. This call would have provided insights into the company’s current financial position and operational progress.
## Company Overview
Summit Therapeutics is a biopharmaceutical oncology company focused on discovering, developing, and commercializing patient-friendly medicinal therapies to address serious unmet medical needs[4]. The company was founded in 2003 and is headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK[4].
Despite the challenging earnings forecast, the positive analyst price targets suggest confidence in the company’s longer-term growth prospects and strategic direction, potentially based on their oncology pipeline and market opportunity rather than immediate financial performance.